Ali Ahmadi

Ali Ahmadi

Auto-generated profile, based on publicly available information

Ali Ahmadi

Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2025 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
OAOmolbanin Sargazi Aval
Omolbanin Sargazi Aval
AAAli Ahmadi
Ali Ahmadi
AAAli Jihad Hemid Al-Athari
Ali Jihad Hemid Al-Athari
HSHamed soleimani samarkhazan
Hamed soleimani samarkhazan
FCFatemeh Sotudeh Chafi
Fatemeh Sotudeh Chafi
MAMojtaba Aghaei
Mojtaba Aghaei
Acute Myeloid Leukemia (AML) presents a formidable challenge in the realm of hematologic malignancies, characterized by the unregulated proliferation of myeloid progenitor cells, leading to severe disruptions in normal hematopoiesis. This review examines the multifaceted role of Galectin-9, a crucial glycan-binding protein in the pathophysiology of AML, emphasizing its potential as both a prognostic biomarker and a therapeutic target. Recent insights into the molecular underpinnings of AML, particularly those involving genetic mutations and cytogenetic abnormalities, illuminate the complex landscape of this disease, where patient outcomes are significantly influenced by individual biological markers. Galectin-9, initially recognized for its involvement in fundamental biological processes such as cell proliferation and immune modulation, has emerged as a pivotal molecule in AML, with expression levels correlating with leukemic cell behavior and clinical prognosis. This review consolidates the extensive literature on Galectin-9, elucidating its role in leukemic transformation and the therapeutic implications of manipulating this pathway. By investigating the intricate relationship between Galectin-9 and AML, we aim to provide a comprehensive understanding that could lead to innovative strategies for managing this aggressive malignancy, offering hope for improved survival outcomes through targeted therapeutic interventions.

10 November 2025 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
FKFatemeh Karimian
Fatemeh Karimian
ZLZohre Loghmani
Zohre Loghmani
NSNader Vazifeh Shiran
Nader Vazifeh Shiran
FMFatemeh Mikanik
Fatemeh Mikanik
MKMelika Khademi
Melika Khademi
AGAhmad Gharehbaghian
Ahmad Gharehbaghian